Type II heat-labile enterotoxin (LT-II) from Escherichia coli causes characteristic morphological changes and accumulation of cyclic AMP in Y-1 adrenal cells, but it is not neutralized by antisera against choleragen (CT) or the classical type I heat-labile enterotoxin (LT-I) from E. coli. The action of purified LT-II on CT-and LT-I-responsive human fibroblasts was investigated and compared with that of CT. Fibroblasts incubated with LT-II or CT had an increased cyclic AMP content as well as a fourfold elevation of membrane adenylate cyclase activity. In membranes, activation of cyclase by toxin was enhanced by NAD, GTP, and dithiothreitol. The effect of LT-II on intact fibroblasts or membranes was increased by trypsin treatment of toxin. Since activation of adenylate cyclase by LT-II was stimulated by NAD, the ability of LT-II to catalyze the [32P]ADP-ribosylation of membrane proteins in the presence of [32P]NAD from control and LT-II-and CT-treated fibroblasts was investigated. Similar proteins were [32P]ADP-ribosylated in membranes exposed to LT-II or CT; LT-II-and CT-specific labeling was significantly decreased in membranes prepared from cells preincubated with either LT-II or CT. These studies are consistent with the hypothesis that LT-II, similar to CT and LT-I, increases cyclic AMP by activating adenylate cyclase through the GTP-dependent ADP-ribosylation of specific membrane proteins.
Cholera toxin (CT), a product of Vibrio cholerae, has been identified as the cause of the profuse secretory diarrhea that occurs during cholera. The effects of CT appear to be a consequence of its ability to activate adenylate cyclase and elevate intracellular cyclic AMP (cAMP) levels in intestinal cells (5, 20, 28) . Similar to CT in function, immunoreactivity, and structure is the type I heat-labile enterotoxin (LT-I) (22) produced by certain strains of Escherichia coli that are involved in the pathogenesis of traveler's diarrhea (2-4, 6, 7, 11, 14, 15, 18, 30) . Both toxins consist of A and B subunits (1, 4, 5, 20, 26, 28) , bind to a ganglioside receptor, GM1 [galactosyl -N -acetylgalactosaminyl -(N -acetyl-neuraminyl)galactosylglucosylceramide; 13, 21] , and activate adenylate cyclase in a NAD-dependent manner (6) . CT and LT-I activate adenylate cyclase by catalyzing the transfer of ADP-ribose from NAD to an amino acid in the stimulatory guanine nucleotide-binding regulatory protein (GS); ADPribosylation of G, appears to increase its sensitivity to GTP, leading to activation of the cyclase catalytic unit and increased intracellular cAMP levels (20) .
Recently, a new cell-associated, heat-labile toxin was identified in a strain of Escherichia coli isolated in Thailand (8, 11a) and named type II heat-labile enterotoxin (LT-II) (24) . LT-II resembles LT-I and CT in several of its biological activities, including the induction of morphological changes and accumulation of cAMP in cultured Y1 adrenal cells, but it is not neutralized by antisera against CT or LT-1 (8, lla). The structural genes for LT-II were cloned and did not hybridize, even under conditions of low stringency that permitted up to 45% base pair mismatch, with the cloned structural genes for LT-I (24). The prototype LT-II was purified and shown to consist of polypeptides that were similar to the A and B polypeptides of CT and LT-I both in * Corresponding author. size and in susceptibility to selective proteolytic cleavage by trypsin (12) . Unlike CT and LT-I, however, the activity of LT-II against Y1 adrenal cells was not highly susceptible to inhibition by ganglioside GM1 (12) . Production of LT-II was also demonstrated in strains of E. coli isolated in Brazil from food and from feces of patients with diarrhea (9) , and one of the E. coli isolates from food was shown to produce a variant of LT-II that could be distinguished from the prototype LT-II both in antigenicity and in several other characteristics (10) . Because of the several differences between the heatlabile enterotoxins of type I (CT and LT-I) and type II (LT-II), the mechanism of action of the prototype LT-II was investigated in detail in human fibroblasts. Our results indicate that, like CT and LT-I, LT-II elevates intracellular cAMP by activating adenylate cyclase through the GTPdependent ADP-ribosylation of G,. (16) .
MATERIALS AND METHODS
Materials. LT-II was purified according to published methods (12) through the final Sephadex G-100 gel filtration step from wild-type E. coli SA53 or from E. coli HB101 (pCP3837), which contains the cloned LT-II structural genes and produces several hundred times more LT-II than SA53. Samples were collected from the leading edge, center, or " Cells in 60-mm dishes were incubated with (i) no toxin, for 12 h; (ii) LT-II, at 0.17 ,ug/ml, for 4 h; (iii) CT, at 10 pug/ml, for 1 h; or (iv) LT-II for 4 h, plus CT for the last 1 h. Cells were then washed three times with 3 ml of Hanks balanced salt solution and incubated with the indicated additions for 7 min at 37°C in 2 ml of Hanks balanced salt solution before cAMP content was assayed.
trailing edge of the LT-II peak, and all samples were purified at least 400-fold with respect to crude sonic extracts of the bacteria. The specific activities of samples from strain SA53
and the experiments in which they were used were: 68 U/,ug of protein ( Fig. 1 and Table 2 ) and 850 U/,ug of protein ( Table  1 ). The specific activities of samples from strain HB101 (pCP3837) and the corresponding experiments were: 15,300 U/,ug of protein (Fig. 2, 3 , and 4 and Tables 3 and 4) " Membranes from fibroblasts were prepared as described in the text.
Activation of LT-II (2.3 p,g/ml) and CT (120 ,ug/ml) was as described. Then, briefly, membranes (-30 ,ug) and activated toxins were mixed with NAD (1 mM) and GTP (20 ,uM) . A reaction mixture was then added to start the adenylate cyclase assay (see the text). ' DTT, 2 mM glycine (pH 8.0) plus 1 mM DTT for 10 min at 30'C. Trypsin, 0.01% in phosphate-buffered saline for 30 min at 37'C; activation was stopped with 10 mg of soybean trypsin inhibitor per ml. DTT plus trypsin, 0.01% trypsin, 20 min at 37'C; activation was stopped with trypsin inhibitor, and then 2 mM glycine (pH 8.0) and 1 mM DTT were added for 10 min at 30'C.
RESULTS AND DISCUSSION
LT-II, added to cultured human fibroblasts, increased the cAMP content of cells after a lag of 3 h (Fig. 1) ; maximal stimulation of threefold over buffer was observed at 12 h. The effect of LT-II on the cAMP content of cells can be enhanced by prior treatment of LT-II with trypsin (0.01%) as shown in Table 1 ; the addition of 3-isobutyl-1-methylxanthine (100 FM) increased cAMP accumulation in LT-IItreated cells but had minimal effect on basal cAMP content. Cells incubated with either LT-II or CT had a two-to threefold increase in cAMP content, and PGE1 increased cAMP content in LT-II-or CT-treated cells as well as control cells (Fig. 2) . Cells treated with LT-II or CT or both had similar stimulation of cAMP levels by isoproterenol (Table 2) .
Membranes prepared from cells incubated with CT or LT-II showed increased adenylate cyclase activity (Fig. 3) . No effect of PT was observed. Adenylate cyclase of membranes treated directly with LT-II also had an increase in activity; this activity was further enhanced by prior treatment of LT-II with DTT or trypsin or both (Table 3) . Even further stimulation of DTT-and-trypsin-treated, LT-II-stimulated adenylate cyclase activity of membranes was achieved by the addition of NAD and GTP (Table 4) .
Toxin-catalyzed ADP-ribosylation of membranes (Fig. 4) , showed that, in membranes from control cells, LT-II, like CT, ADP-ribosylated peptides of 47 and 42 kilodaltons, " The procedure was as described in Table 3 . The ability of LT-II to ADP-ribosylate membrane proteins was further studied by characterization of its ability to catalyze NAD hydrolysis and ADP-ribosyltransferase activity (Table 5) . LT-II has the ability to catalyze NAD hydrolysis and ADP-ribose transfer to agmatine, a model substrate.
These experiments showed that LT-II increased intracellular cAMP content of human fibroblasts, apparently by increasing adenylate cyclase activity through ADP-ribosylation of Gs. Thus, the mechanism of LT-II action is strikingly similar to that of CT. ADP-ribosylation seems to be a conserved function of the A subunits. The activity of the native A subunit appears to be latent, because proteolytic digestions and thiol are required to unmask the transferase activity of CT (19) , LT-I (22) , and LT-II. Although either " Trypsin-and thiol-activated LT-II (6 ,ug/ml) or CT (1 ,g/ml) as described in 
